Dowling & Yahnke’s BioAtla BCAB Stock Holding History

Dowling & Yahnke’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-152	Closed	-$224K	–	380
2021 Q3	$224K	Hold	152	–	–	0.01%	340
2021 Q2	$322K	Buy	+152	New	+$343K	0.02%	298

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Dowling & Yahnke's BCAB Position: Q4 2021 in Review

Dowling & Yahnke sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 152 shares — an estimated $224K sold.

Dowling & Yahnke first reported a position in BCAB in Q2 2021 and held it in 2 quarters. The position peaked at $322K in Q2 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

Dowling & Yahnke reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
Dowling & Yahnke sold 152 BioAtla shares in Q4 2021, an estimated $224K.
Dowling & Yahnke first reported a position in BioAtla in Q2 2021 and held it in 2 quarters.
Dowling & Yahnke's BioAtla position peaked at $322K in Q2 2021.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Dowling & Yahnke's 13F filing for Q4 2021, filed 10 Feb 2022.